Medicines & Healthcare products Regulatory Agency

MHRA Central Freedom of Information Team
10 South Colonnade
Canary Wharf
London
E14 4PU

foi.request@mhra.gov.uk.

MHRA Website

[redacted]

Our Ref: **FOI2026/00608**

11 June 2026

Dear [redacted]

Thank you for your Freedom of Information (FoI) request received on 8 June. You wrote:

> *I am writing to request specific adverse drug reaction (ADR) data from the Yellow Card scheme database. Could you please provide the total number of reported cases of alopecia associated with the use of strontium ranelate (Protelos / Osseor) notified to the MHRA up to the latest available update? If possible, I would appreciate it if the data could include a breakdown by year of reporting and the seriousness of the cases.*

MHRA Response

We can confirm that the Agency holds this information. However, the information is exempt under Section 21(1) of the Freedom of Information Act because the information is reasonably accessible to you, as it is already in the public domain.

Further information can be found on: https://ico.org.uk/for-organisations/foi/freedom-of-information-and-environmental-information-regulations/section-21-information-accessible-to-the-applicant-by-other-means/

However, to be helpful you can find the information you seek at: https://yellowcard.mhra.gov.uk/idaps. Interactive Drug Analysis Profiles (iDAPs) contain complete listings for all medicines and vaccines of all UK spontaneous suspected adverse reactions received by the MHRA and are available to view on this website. On this platform, you will be able to search for the specified medicines and find the reported suspected adverse reactions associated with them.

Within the iDAP you can view the types of reactions that have been reported for strontium ranelate products. These are displayed by primary System Organ Class (SOC) and reported to the level of preferred terms (PTs) as defined by the Medical Dictionary for Regulatory Activities (MedDRA). MedDRA is a standardised medical terminologies tool. For Yellow Card reports referencing alopecia, please select the SOC ‘Skin and Subcutaneous Tissue Disorders’ and the High Level Group Term (HLGT) ‘Skin appendage conditions’.

The graphs and tables within the ‘Total Report Profile’ and ‘Total Reaction Profile’ tabs are dynamic for all products. The filters on the left-hand side allow you to interact and filter the

data as you wish. Using these filters, you can breakdown the data by the year reports were received and the reported seriousness of the cases (Fatal, non-serious and serious).

If you have any queries about this letter, please contact us quoting the reference number above.

Yours sincerely,

MHRA Central Freedom of Information Team
Medicines & Healthcare products Regulatory Agency

Your right to complain under the Freedom of Information Act

If you are not happy with this response you may request an internal review by e-mailing foi.request@mhra.gov.uk or by writing to: MHRA Central Freedom of Information Team, 10 South, Colonnade, Canary Wharf, London, E14 4PU

Any request for an internal review must be received by us within 40 working days of the date of this letter. Please note we are not obliged to provide a review if it is requested after more than 40 working days.

If you are not content with the outcome of the internal review, you may apply directly to the Information Commissioner's Office for a decision. Generally, the Commissioner cannot make a decision unless you have exhausted our own complaints procedure. The Information Commissioner can be contacted at: The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

Website: https://ico.org.uk/make-a-complaint/foi-and-eir-complaints/foi-and-eir-complaints/ or telephone 0303 123 1113

Re-use of our information